Advertisement
Canada markets close in 1 hour 29 minutes
  • S&P/TSX

    21,964.70
    +79.32 (+0.36%)
     
  • S&P 500

    5,104.78
    +56.36 (+1.12%)
     
  • DOW

    38,277.12
    +191.32 (+0.50%)
     
  • CAD/USD

    0.7318
    -0.0005 (-0.07%)
     
  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     
  • Bitcoin CAD

    87,446.22
    -955.60 (-1.08%)
     
  • CMC Crypto 200

    1,334.22
    -62.32 (-4.46%)
     
  • GOLD FUTURES

    2,352.00
    +9.50 (+0.41%)
     
  • RUSSELL 2000

    2,003.86
    +22.75 (+1.15%)
     
  • 10-Yr Bond

    4.6710
    -0.0350 (-0.74%)
     
  • NASDAQ

    15,928.02
    +316.26 (+2.03%)
     
  • VOLATILITY

    15.09
    -0.28 (-1.82%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6837
    +0.0016 (+0.23%)
     

Stocks in play: The Yield Growth Corp.

Announced that on December 2, 2019 its subsidiary Yield Botanicals Inc. entered into a non binding LOI to acquire Canniva Capital Inc., which is developing CBD assets in Europe. Yield Growth's wholly owned subsidiary Yield Botanicals has a planned business to create a hemp extraction facility in Oregon to produce CBD from organically grown hemp. The proposed terms of the acquisition are that Yield Botanicals will acquire all the outstanding and issued shares of Canniva by issuing one share and one warrant in Yield Botanicals to acquire each share of Canniva. The proposed acquisition is subject to Canniva raising $1,000,000 at $0.10 per share. Once the acquisition is complete, Yield Botanicals has an obligation to go public and obtain a stock exchange listing either by Initial Public Offering or by reverse merger with a listed company within 6 months. Upon listing Yield Growth is expected to own 50,000,000 shares and 70% of the listed entity. The Yield Growth Corp. shares BOSS:CNX are trading unchanged at $0.26.

Read: Oncolytics Biotech to Highlight Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue at the Fifth Annual Oncolytic Virotherapy Conference